Richard D. Truesdell, Jr.

Davis Polk advised BRP Group, Inc. on its $258.1 million follow-on offering of 8,750,000 shares of Class A common stock. The shares of Class A common stock are listed on the Nasdaq Global…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Esperion Therapeutics, Inc. of $250 million aggregate principal amount of…

Davis Polk advised the representative of the several underwriters in connection with the SEC-registered offering of 38,000,000 shares of common stock of Plug Power Inc. for $845.5…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered public debt offering by Bristol-Myers Squibb Company,…

Davis Polk advised the underwriter in connection with a block trade of 663,394 shares of Class A common stock of Bandwidth Inc. by VIP II Nominees Limited (for the benefit of Vitruvian…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited of $575 million aggregate principal amount of its 0.000%…

Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…

Davis Polk advised Gatos Silver, Inc. on its SEC-registered initial public offering of 21,430,000 common shares for total gross proceeds of approximately $150 million. In addition, Gatos…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…